Investigators at University of Notre Dame Discuss Findings in Adenocarcinoma [Targeting Kras for the Potential Treatment of Pancreatic Ductal Adenocarcinoma: Recent Advancements Provide Hope (Review)].

Předmět:	PANCREATIC duct RAS oncogenes ADENOCARCINOMA ONCOGENES DRUG development PANCREATIC intraepithelial neoplasia
Zdroj:	Drug Week; 11/17/2023, p529-529, 1p
Abstrakt:	A recent report from the University of Notre Dame discusses the importance of targeting the Kirsten rat sarcoma viral oncogene homolog (KRAS) in pancreatic ductal adenocarcinoma (PDAC). KRAS is a frequently mutated oncogene in solid tumors, with over 90% of PDAC cases being driven by mutations in this gene. However, previous attempts to target KRAS have been unsuccessful due to its small size and lack of distinct drug-binding pockets. The review highlights recent advancements in the development of mutation-specific drugs and direct KRAS inhibitors for the treatment of PDAC. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu